1Wright EM, Loo DD, Hirayama BA. Biology of human :odium glucose transporters. Physiol Rev, 2011,91 : 733-794.
2Zambrowicz B, Freiman J,Brown PM, et al. LX4211 ,adual SOLT1/ SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther, 2012,92 : 158-169.
4Chao EC, Henry RR. SGLT2 inhibition-a novel strategy for dia- betes treatment. Nat Rev Drug Discov, 2010,9:551-559.
5Washburn WN,Poucher SM. Different iating sodium-glucose co-trans- porter-2 inhibitors in development for the treatment of type 2 di- abetes mellitus. Expert Opin .Investig Drugs, 2013,22 : 463-486.
6Stenl6f K,Cefalu WT, Kim KA, et al. Efficacy and safety of canagli- flozin monotherapy in subjects with type 2 diabetes mellitus inade- quately controlled with diet and exercise. Diabetes Obes Metab, 2013,15:372-382.
7Fujita Y, Inagaki N. Renal sodium glucose cotransporter 2 in- hibitors as a novel therapeutic approach to treatment of type 2 diabetes: clinical data and mechanism of action. J Diabetes In- vestig, 2014,5 : 265-275.
8Poudel RR. Renal glucose handling in diabetes and sodium glu- cose cotransporter 2 inhibition. Indian J Endocrinol Metab, 2013,17:588-593.
9Macdonald FR,PeeI JE,Jones HB,et al. The novel sodium glu- cose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats. Diabetes Obes Metab, 2010,12 : 1004-1012.
10Thomas L, Grempler R, Eckhardt M, et al. Long-term treatment with empagliflozin, a novel, potent and selective SC, LT-2 inhibi- tor, improves glycaemic control and features of metabolic syn- drome in diabetic rats. Diabetes Obes Metab, 2012,14:94-96.
